| 2.06 0.01 (0.49%) | 08-18 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.49 | 1-year : | 2.91 |
| Resists | First : | 2.14 | Second : | 2.49 |
| Pivot price | 1.9  |
|||
| Supports | First : | 1.81 | Second : | 1.62 |
| MAs | MA(5) : | 2.04  |
MA(20) : | 1.87 |
| MA(100) : | 2.23 |
MA(250) : | 2.7 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 81.4 |
D(3) : | 80.7 |
| RSI | RSI(14): 61.2 |
|||
| 52-week | High : | 4.94 | Low : | 1.6 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ BDTX ] has closed below upper band by 24.5%. Bollinger Bands are 20.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.08 - 2.09 | 2.09 - 2.1 |
| Low: | 2 - 2.01 | 2.01 - 2.02 |
| Close: | 2.04 - 2.06 | 2.06 - 2.07 |
Black Diamond Therapeutics, Inc. is a biotechnology enterprise dedicated to discovering, advancing, and bringing to market therapeutic agents specifically designed for patients with genetically characterized tumors. A core part of its pipeline is BDTX-189, an irreversible small molecule inhibitor. This compound is engineered to neutralize oncogenic proteins driven by non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) driver mutations. The firm is also progressing BDTX-1535, a brain-penetrant inhibitor addressing a range of EGFR mutations, including conventional, inherent resistance, and acquired resistance forms. Concurrently, it is advancing BDTX-4933, another brain-penetrant inhibitor targeting oncogenic BRAF alterations across Class I, II, and III categories. Black Diamond maintains a strategic alliance with OpenEye Scientific Software, Inc. Established in 2014, the company was initially known as ASET Therapeutics, Inc. before adopting its current name, Black Diamond Therapeutics, Inc., in January 2018. Its corporate headquarters are situated in Cambridge, Massachusetts.
Sat, 15 Aug 2026
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Sat, 08 Aug 2026
Renaissance Technologies LLC Has $3.50 Million Stock Holdings in Black Diamond Therapeutics, Inc. $BDTX - MarketBeat
Fri, 07 Aug 2026
BDTX Stock Price, Quote & Chart - ChartMill
Wed, 05 Aug 2026
Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Yahoo Finance
Mon, 06 Jul 2026
Black Diamond Therapeutics: Positive Phase 2 Results Offer An Upside (NASDAQ:BDTX) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 57 (M) |
| Shares Float | 52 (M) |
| Held by Insiders | 0.6 (%) |
| Held by Institutions | 66.9 (%) |
| Shares Short | 5,850 (K) |
| Shares Short P.Month | 4,980 (K) |
| EPS | -0.75 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.96 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -18.6 % |
| Return on Equity (ttm) | -35.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.8 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -34 (M) |
| Levered Free Cash Flow | -26 (M) |
| PE Ratio | -2.75 |
| PEG Ratio | 0 |
| Price to Book value | 1.05 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.47 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|